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Abstract
Background: Although older cancer survivors commonly report psychosocial problems, the impact of both cancer
and ageing on the occurrence of these problems remains largely unknown. The evolution of depression, cognitive
functioning, and fatigue was evaluated in a group of older cancer patients in comparison with a group of younger
cancer patients and older persons without cancer.
Methods: Older (≥70 years) and younger cancer patients (50 – 69 years) with breast or colorectal cancer stage I - III,
and older persons without cancer (≥70 years) were included. Data were collected at baseline and one year follow-up
and were available for 536 persons. Depression was evaluated with the 15-item Geriatric Depression Scale. Cognitive
functioning was measured with the cognitive functioning subscale of the European Organization for Research and
Treatment of Cancer. Fatigue was measured with a Visual Analogue Scale. Risk factors for depression, cognitive
functioning, and fatigue were analysed using multivariate logistic regression analyses. Risk factors included cancer- and
ageing-related factors such as functional status, cancer treatment, and comorbidities.
Results: The evolution of psychosocial problems was similar for the group of older (N = 125) and younger cancer
patients (N = 196): an increase in depression (p < 0.01), slight worsening in cognitive functioning (p = 0.01), and no clear
change in fatigue. Also, compared to the group of people without cancer (N = 215), the differences were small and after
one year of follow-up only depression was more frequent in older cancer patients compared to older persons without
cancer (18 % versus 9 %, p = 0.04). In multivariate analyses the main risk factors for psychosocial problems after one year
follow-up were changes in functional status and presence of baseline depression, fatigue, or cognitive impairment.
Conclusion: Over the course of one year after a diagnosis of cancer, cancer patients face increasing levels of depression
and increasing difficulties in cognitive functioning. The main risk factor for psychosocial problems was presence of
the problem at baseline. This calls for regular screening for psychosocial problems and exchange of information
on psychosocial functioning between different health care providers and settings during the treatment and
follow-up trajectory of cancer patients.
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Background
The number of cancer patients and cancer survivors is
increasing and will continue to increase in the coming
decades [1, 2]. Furthermore, not only the number of
older persons that are diagnosed with cancer is high and
increasing. The number of cancer survivors is increasing
as well, due to the additional improvement in cancer
treatment. Whereas cancer used to be a fatal disease, it
is now developing towards a chronic or even curable
disease [3]. A diagnosis and subsequent treatment of
cancer can have a substantial and possibly long-lasting
psychosocial impact on patients’ lives. This problem was
brought to our attention by two reports of the Institute
of Medicine in the US: the 2006 publication “From
Cancer Patient to Cancer Survivor: Lost in Transition”
and the 2008 publication “Cancer Care for the Whole
Patient: Addressing Psychosocial Health Needs” [3, 4].
Psychosocial care for cancer patients and survivors has
received increased attention since. In Belgium for ex-
ample, hospitals receive additional funding for psycho-
social care for cancer patients since 2008.
Despite growing attention for the issues cancer survi-
vors face, only a limited number of initiatives and research
projects specifically focus on older cancer patients and
survivors. Nevertheless, the group of older cancer patients
is the largest and fastest growing group of cancer patients.
Currently, the mean age at cancer diagnosis is 66 years
and 46 % of all new cancer patients are aged 70 years or
older [5]. Despite representing such an important group,
our knowledge of psychosocial problems in older cancer
patients remains inadequate [6].
Previous research that focused on psychosocial prob-
lems in older cancer patients was mostly cross-sectional,
and did not simultaneously compare older cancer pa-
tients with healthy controls or younger cancer patients.
Hence, previous studies were unable to disentangle the
mutual impact of both cancer and ageing, whereas both
are likely to have a substantial impact on the patients’
psychosocial functioning.
With respect to the impact of cancer, research has
often shown that older cancer survivors fare worse,
physically as well as mentally, compared to older persons
of the same age without cancer [7, 8]. A recent study
found that older cancer patients indeed reported poorer
physical functioning compared to healthy controls, but
did not find support for a difference in psychological
and cognitive functioning [6].
With respect to the impact of ageing, findings are in-
consistent. Several studies show that younger cancer pa-
tients report more psychological problems compared to
older cancer patients [9, 10]. However, older and youn-
ger cancer patients were similar with respect to the most
common cancer-related symptoms such as lack of en-
ergy and difficulty concentrating [10]. Furthermore, the
lower levels of psychosocial problems in older cancer pa-
tients may be due to less aggressive cancer treatments,
and older patients might be more reluctant to report
problems because they fear additional testing and treat-
ments and they view their health problems as a normal
part of ageing [10]. The measurement tools that were
used might also play an important role, as these are not
always adjusted for use in older persons. For example,
the identification of depression in older persons asks for
a somewhat different approach compared to younger per-
sons as older persons less commonly disclose affective
symptoms such as sadness, and instead tend to present
with trouble concentrating and fatigue [11, 12].
To address psychosocial problems in older cancer pa-
tients, the evolution of depression, cognitive functioning,
and fatigue was evaluated in a group of older cancer pa-
tients. Furthermore, the frequency and severity of these
problems in older cancer patients was compared with
younger cancer patients and with older persons without
cancer. Finally, the influence of ageing- and cancer-
related problems on the occurrence of depression, cogni-
tive impairment, and fatigue after one year of follow-up
was evaluated.
Methods
The data for this study were collected as part of a pro-
spective observational cohort study; the KLIMOP-study.
The design of this study has been published previously
[13]. Older cancer patients (OCP; ≥70 years), younger
cancer patients (YCP; 50 – 69 years), and older primary
care patients without a history of cancer, except non-
melanoma of the skin (ONC; ≥70 years) were included.
To date, there is no clear age cut-off or definition of an
older (cancer) patient, in this study older was defined as
a person aged 70 years and above [14]. In the present
study, the included cancer patients were patients with an
incident diagnosis of breast or colorectal cancer stage I
– III. Cancer patients were recruited through seven hos-
pitals in Belgium and the Netherlands within three
months after cancer diagnosis. A priori sample size cal-
culations yielded a total needed sample size between 50
and 313 participants per group (depending on the preva-
lence of for example depression in the control group),
we aimed to recruit 320 patients per group per country,
enabling within-country analyses [13].
ONC were recruited through general practices and
home nurses in the same region. General practitioners
asked all consecutive eligible patients (70 years and
above, no history of cancer) to participate until 20 pa-
tients per general practitioner agreed to participate.
Exclusion criteria for OCP, YCP, and ONC were the
inability to speak Dutch, a formal diagnosis of dementia,
and an estimated life expectancy less than six months.
Data of all patients with at least one year follow-up who
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were included in the study between June 2010 and August
2012 were used. At time of this study recruitment of
patients was still ongoing.
Data collection
Data collection and management were identical in the
three groups. Data were collected through personal in-
terviews or self-administered questionnaires at baseline
(T0) and at one-year follow-up (T1). In one hospital,
baseline data collection was integrated in a routine geri-
atric assessment. Therefore, data collection was slightly
different in this hospital and did not include the same
measurement tool for cognitive functioning and fatigue.
For all patients, medical information was retrieved from
the medical records of the hospital (for cancer patients)
or the general practitioner (for older persons without
cancer).
Dependent variables
Depression
Depression was evaluated with the 15-item Geriatric De-
pression Scale (GDS-15), which was especially designed
to screen for depression in an older population [15]. The
total sum score ranges from 0 to 15. The mean score
was used to indicate the severity of depression. A score
of ≥5 was used as cut-off for the frequency of depres-
sion, for which sensitivity and specificity against a stand-
ard clinical interview have been shown to be 91 % and
72 % respectively. Furthermore, the GDS-15 has a high
level of internal consistency (Cronbach’s alpha = 0.80)
[16]. In our study, Cronbach’s alpha was 0.72 for the
total population, 0.70 in OCP, 0.77 in YCP, and 0.68 in
ONC.
Subjective cognitive functioning
Subjective cognitive functioning was measured with the
cognitive functioning subscale of the quality of life ques-
tionnaire of the European Organization for Research and
Treatment of Cancer (EORTC QLQ-C30) [17]. This sub-
scale consists of two items (“During the past week have
you had difficulty in concentrating on things, like read-
ing a newspaper or watching television?” and “During
the past week have you had difficulty remembering
things?”). Based on the EORTC QLQ-C30 manual, cog-
nitive functioning was recoded in a score ranging from 0
to 100, with higher scores representing better functioning
[18]. The mean score was used to indicate the severity of
cognitive impairment. The frequency of cognitive impair-
ment was operationalized by using the lowest functioning
quartile as cut-off, this corresponded to a score <67 in all
three groups.
The internal consistency for the cognitive functioning
subscale has been shown to be fair, with Cronbach’s
alpha ranging between 0.52 and 0.73 [17]. In our study,
Cronbach’s alpha was 0.47 for the total population, 0.57
in OCP, 0.65 in YCP, and 0.34 in ONC.
Fatigue
A Visual Analogue Scale (VAS) was used for measuring
fatigue. Patients were asked: ‘On a scale of 0 to 10, how
would you rate your fatigue over the past 24 h?’. The
mean score was used to indicate the severity of fatigue.
A cut-off ≥4 was used to define the frequency of fatigue.
Covariables
Cancer-related variables
As cancer-related variables, cancer type (breast and
colorectal cancer), cancer stage (I, II, III), and the cancer
treatment modalities received in the first year after can-
cer diagnosis (surgery, chemotherapy, radiotherapy, hor-
monal therapy, and targeted therapy) were considered.
As several combinations are possible, cancer treatment
was operationalized according to physical impact: no
treatment; surgery only; surgery and radiotherapy or
hormonal therapy or both; surgery and chemotherapy
with or without any combination of radiotherapy, hormo-
nal therapy, and targeted therapy; other combinations.
The group of ‘other’ cancer treatments consisted of people
who received no surgery but instead any of the following
combinations: chemotherapy; chemo- and radiotherapy;
chemo- and targeted therapy; hormonal therapy.
Functional status is also a cancer-related factor, as
cancer treatment often results in decline of functional
status. However, for pragmatic reasons this is discussed
under the ageing-related variables.
Ageing-related variables
As ageing-related factors, baseline age, comorbidity, num-
ber of drugs taken as chronic medication, and change in
functional status between T0 and T1 were considered.
Comorbidity was measured with the Charlson Comor-
bidity Index (CCI), which provides a weighted score of
19 comorbid conditions [19]. The total score is derived
by summing the assigned weights of all comorbid condi-
tions. It ranges from 0 to 37 maximum; higher scores
indicate multiple and/or more severe conditions. The
mean CCI score was presented. In addition to the CCI,
the mean number of drugs taken as chronic medication
was also included.
Functional status was measured by Activities of Daily
Living (ADL) using the Katz Index [20] and by Instru-
mental Activities of Daily Living (IADL) using the Law-
ton IADL-scale [21]. The Katz Index consists of six
items and the total sum score ranges from 0 (dependent)
to 6 (independent). The Lawton IADL-scale consists of
eight items in women and five items in men. The total
sum score ranges from 0 (dependent) to 8 (independent)
in women, and from 0 (dependent) to 5 (independent) in
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men. Functional impairment was defined as dependency on
at least one domain of ADL (score <6) or IADL (a score <8
in women or <5 in men). Change in functional status was
operationalized as follows: not impaired (independent at
T0 and T1), was impaired (dependent at T0; independent
at T1), became impaired (independent at T0; dependent
at T1), persistently impaired (dependent at T0 and T1).
Socio-demographic variables
Socio-demographic variables include sex (men versus
women), living situation (living alone, with partner, with
family or friends, institutionalized), and educational level
(age at which they left school; <15, 15 – 18, >18 years).
Ethics
The study protocol was approved by the Ethical Review
Board of KU Leuven and UZ Leuven (S52097 – ML6279)
(Belgium) and the Maastricht University Medical Centre
(NL31414.068.10) (the Netherlands). All patients signed
informed consent.
Analysis
Patients were excluded from analyses if they were lost to
follow or deceased at T1, skipped data collection at T1,
or received a diagnosis of cancer during follow-up (only
applicable for ONC), for more detail see Fig. 1.
Socio-demographic and clinical characteristics of the
study population are presented as the mean and standard
deviation (SD) for continuous variables and as numbers
and proportions for categorical variables. Comparisons
between different groups were performed using the
Wilcoxon-Mann-Whitney test for continuous data and
the chi square test for categorical data. Comparisons
within groups were performed using Wilcoxon signed
ranks test for continuous data and the McNemar test
for categorical data. A p-value < 0.05 was considered to
be statistically significant throughout all analyses.
The relationship between independent and dependent
variables at T1 was tested with multivariate logistic regres-
sion analyses. All analyses were adjusted for the baseline
value of the dependent variable and for the same cancer-
and ageing-related variables. Because the impact of both
cancer and ageing on the dependent variables remains
unknown, the possibility of interaction between age
and cancer in the group of OCP and ONC and between
age and cancer treatment in the group of OCP and
YCP was evaluated. This was evaluated visually as well as
statistically. Based on these analyses no indication for
interaction between age and cancer or cancer treatment
was found.
Due to colinearity between cancer treatment, type of
cancer, and cancer stage, only the different combinations
of cancer treatment were included in the model. The fit
of the model was tested with the Hosmer and Leme-
show’s goodness-of-fit test.
As described above, the baseline measurement for cog-
nitive functioning and fatigue was not collected for a
subgroup of OCP for whom data collection was inte-
grated in a routine geriatric assessment. Also, for some
patients data on depression and functional status were
missing. Therefore, a sensitivity analysis was performed
to assess the influence of these missing values, making a
worst- and best-case scenario by imputing missing
values as either a normal or an abnormal score.
Younger cancer patients
KLIMOP-study
Older cancer patients Older persons without cancer
Included between June 2010 and August 2012:
No follow-up data:
Available for analyses:
N = 269
Lost to follow-up: N = 50
Skipped one-year follow-up: N = 18
Deceased: N = 5
Total: N = 196 
N = 323
Lost to follow-up: N = 79
Skipped one-year follow-up: N = 20
Received a diagnosis of cancer: N = 4
Deceased: N = 5
Total: N = 215
N = 180
Lost to follow-up: N = 37
Skipped one-year follow-up: N = 9 
Deceased: N = 9
Total: N = 125
Patients with no measurement for subjective 
cognitive functioning and fatigue: 
N = 35
Fig. 1 Flow-chart: patient population of the KLIMOP-study
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Furthermore, the influence of sex and type of cancer was
assessed by stratifying the analyses for these variables.
Statistical analyses were performed using the STATA
statistical software package version 11 (StataCorp LP,
College Station, TX).
Results
Description and follow-up of the population
Seven hundred and twenty-two patients were included
in the KLIMOP-study between June 2010 and August
2012. During the one-year follow-up period, 9 OCP, 5
YCP, and 5 ONC died (p = 0.06 for OCP versus YCP; p
= 0.03 for OCP versus ONC). Twenty-two percent were
lost to follow-up and 6 % of the patients skipped data
collection at T1 (see Fig. 1). The proportion of OCP and
YCP that were lost to follow-up or skipped data collec-
tion at T1 was comparable (p = 0.79). The same was true
for OCP versus ONC (p = 0.21).
For the outcome variables of interest, depression, cog-
nitive functioning, and fatigue, baseline values for per-
sons available for analyses were similar compared to
those lost to follow-up (see Additional file 1: Table S1).
Only the severity of depression was slightly higher for
ONC who were lost to follow-up compared to those in-
cluded in the analyses (p < 0.01), however the absolute
difference was small (difference of 0.69) and the frequency
of depression was comparable in both groups (p = 0.24).
For socio-demographic and clinical characteristics, OCP
available for analyses were similar to those lost to follow-
up. Only for cancer stage, the proportion of excluded
OCP with stage II cancer was lower, and the proportion
with stage III cancer was higher, compared to included
OCP (p < 0.01). YCP and ONC available for analyses at T1
were comparable to those lost to follow-up (see Additional
file 1: Table S1).
Baseline characteristics
All patients were Caucasian, with the exception of two
YCP. OCP and ONC were comparable with respect to
age, living conditions, educational level, and functional
status (see Table 1). The proportion of women was higher
in OCP compared to ONC, due to the recruitment of
breast cancer patients (p < 0.001). The mean CCI score,
and mean number of drugs taken as chronic medication
was higher for ONC compared to OCP (p < 0.01).
For OCP versus YCP, the proportion of men and
women was similar (p = 0.33), as well as the proportion
of breast and colorectal cancer patients (p = 0.66). OCP
differed from YCP with respect to age, living situation,
educational level, functional status, CCI, number of drugs
taken as chronic medication, and cancer treatments re-
ceived (see Table 1). OCP and YCP also differed for cancer
stage at diagnosis. However, when stratified according to
cancer type, this was only true for breast cancer patients
(stage I: 21 % and 45 %; stage II: 74 % and 44 %; stage III:
5 % and 12 % respectively).
Influence of ageing and cancer
Figure 2 shows the severity and frequency of the selected
problems in the three groups at T0 and T1. Details of
the differences between and within groups are provided
in Table 2.
Depression
The frequency of depression increased significantly from
9 % to 18 % in OCP (p = 0.04) and from 11 % to 19 % in
YCP (p = 0.02), while it remained stable in ONC (p = 0.80).
At T1, the frequency of depression was significantly higher
in OCP compared to ONC (p = 0.04), but the severity was
similar for OCP and ONC (p = 0.10). For OCP and YCP,
the severity and frequency of depression was similar at T0
and T1 (see Fig. 2 and Table 2).
Multivariate analyses showed that cancer treatment,
especially the combination of surgery with chemother-
apy, significantly increased the risk of depression (OR:
3.26; 95 % CI: 1.20 - 8.87), while ageing-related factors
such as chronological age, number of drugs taken as
chronic medication, and comorbidity were not associ-
ated with depression (see Table 3). Changes in functional
status were associated with depression. People who be-
came impaired (OR: 3.99; 95 % CI: 1.14 - 13.90) or were
persistently impaired (OR: 7.78; 95 % CI: 2.60 - 23.29) in
functional status were almost four and eight times more
likely to be depressed at T1 compared to people who
were not impaired. Other factors that predicted the
occurrence of depression were depression at T0 (OR:
10.39; 95 % CI: 4.65 - 23.22) and living alone (OR: 2.70;
95 % CI: 1.31 - 5.56).
Cognitive functioning
The frequency and severity of cognitive impairment in-
creased slightly in both cancer groups, although the dif-
ference was only significant for the severity of cognitive
functioning in OCP (p < 0.01) (see Table 2). In ONC cog-
nitive impairment remained stable. At both T0 and T1,
OCP and YCP were comparable with respect to fre-
quency and severity of cognitive impairment. OCP re-
ported better cognitive functioning compared to ONC at
T0 (p = 0.04).
Multivariate analyses showed that only impaired cog-
nitive functioning at T0 (OR: 4.21; 95 % CI: 2.56 - 6.93)
and persistent impairment in functional status (OR: 2.34;
95 % CI: 1.21 - 4.54) predicted cognitive impairment at
T1 (see Table 3).
Fatigue
The frequency of fatigue remained stable in OCP at
53 %, in YCP it increased from 52 % to 60 %, and in
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Table 1 Baseline population characteristics (N = 536)
Younger cancer patients Older cancer patients Older persons
without cancer
N = 196 N = 125 N = 215
N P valuea N P valueb N
Socio-demographic variables
Gender
Male 28 14 % 0.33 23 18 % 0.00 77 36 %
Female 168 86 % 102 82 % 138 64 %
Living situation
Alone 28 14 % 0.00 39 31 % 0.14 70 33 %
With partner 160 82 % 72 58 % 134 62 %
With friends/family 8 4 % 6 5 % 7 3 %
Institutionalized 0 8 6 % 4 2 %
Age at leaving school
<15 years 18 9 % 0.00 33 26 % 0.72 67 31 %
15 – 18 years 95 48 % 60 48 % 98 46 %
>18 years 76 39 % 28 22 % 48 22 %
Missing 7 4 % 4 3 % 2 1 %
Ageing-related variables
Age (years): mean ± SD 59.53 ±5.30 0.00 77.18 ±5.17 0.13 78.07 ±5.41
Number of drugs: mean ± SD 2.29 ±2.41 0.00 4.22 ±3.45 0.01 5.07 ±3.33
CCI: mean ± SD 0.30 ±0.80 0.01 0.50 ±0.70 0.00 1.36 ±1.48
Missing 3 5 47
Functional status
Impaired 87 44 % 0.00 90 72 % 0.10 136 63 %
Missing 1 1 % 0 / 0 /
Cancer-related variables
Cancer site
Breast 150 77 % 0.66 93 74 %
Colorectal 46 23 % 32 26 %
Cancer treatment 0.00
No treatment 0 0 % 1 1 %
Surgery only 19 10 % 20 16 %
Surgery and RT/HT or both 70 36 % 67 54 %
Surgery and CT with or without any combination of RT/HT/TT 100 51 % 32 26 %
Other c 7 4 % 4 3 %
Unknown 0 / 1 1 %
Cancer Stage 0.00
I 69 35 % 21 17 %
II 75 38 % 71 57 %
III 44 22 % 14 11 %
Unknown 8 4 % 19 15 %
SD, standard deviation; CCI, Charlson Comorbidity Index; RT, radiotherapy; HT, hormonal therapy; CT, chemotherapy; TT, targeted therapy
aDifferences between older cancer patients and younger cancer patients
bDifferences between older cancer patients and older persons without cancer
cOther cancer treatments consisted of people who received no surgery but instead any of the following combinations: chemotherapy only (N = 2), chemo- and
radiotherapy (N = 6), chemo- and targeted therapy (N = 1), hormonal therapy only (N = 2)
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Fig. 2 (See legend on next page.)
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ONC the frequency of fatigue increased from 57 % to
62 %. However, this increase was not significant, neither
in YCP (p = 0.12), nor in ONC (p = 0.26). Similarly, the
severity of fatigue increased slightly, but not signifi-
cantly. At both time points, the frequency and severity
of fatigue was similar for OCP and YCP, and for OCP
and ONC.
In multivariate analyses the association between can-
cer treatment and occurrence of fatigue was not signifi-
cant (see Table 3). For functional status, results showed
that especially people who became impaired were at risk
of fatigue (OR: 2.14; 95 % CI: 1.04 - 4.43). One other
ageing-related factor that predicted fatigue was the in-
creasing number of drugs taken as chronic medication
Table 2 Frequency and severity of psychosocial problems at baseline and one-year follow-up
Younger cancer patients P value between
group differencea
Older cancer
patients
P value between
group differenceb
Older persons
without cancer
DEPRESSION: N = 163 N = 101 N = 192
Severity: mean (±SD)
Baseline 1.86 (±2.28) 0.10 2.15 (±2.30) 0.10 1.78 (±2.03)
After one year 2.51 (±2.85) 0.77 2.34 (±2.29) 0.10 1.86 (±2.09)
P value within group difference 0.02 0.35 0.58
Frequency: N (%)
Baseline 18 (11 %) 0.58 9 (9 %) 0.87 16 (8 %)
After one year 31 (19 %) 0.81 18 (18 %) 0.04 18 (9 %)
P value within group difference 0.02 0.04 0.80
COGNITIVE FUNCTIONING: N = 195 N = 89 N = 214
Severity: mean (±SD)
Baseline 84.36 (±22.36) 0.40 88.01 (±17.59) 0.04 85.12 (±16.41)
After one year 82.05 (±21.27) 0.90 82.58 (±19.28) 0.65 84.27 (±17.07)
P value within group difference 0.10 0.01 0.48
Frequency: N (%)
Baseline 54 (28 %) 0.08 16 (18 %) 0.44 47 (22 %)
After one year 60 (31 %) 0.40 23 (26 %) 0.47 47 (22 %)
P value within group difference 0.51 0.14 1.00
FATIGUE: N = 187 N = 79 N = 211
Severity: mean (±SD)
Baseline 3.99 (±2.82) 0.41 3.67 (±2.77) 0.17 4.14 (±2.30)
After one year 4.45 (±2.66) 0.30 4.10 (±2.49) 0.30 4.42 (±2.31)
P value within group difference 0.08 0.24 0.12
Frequency: N (%)
Baseline 98 (52 %) 0.91 42 (53 %) 0.57 120 (57 %)
After one year 112 (60 %) 0.31 42 (53 %) 0.19 130 (62 %)
P value within group difference 0.12 1.00 0.26
Depression, cognitive functioning, and fatigue are presented as the mean score – indicated as the severity – and the proportion – indicated as frequency.
Depression was measured with the 15-item Geriatric Depression Scale, range 0 – 15, higher scores indicate more depression, cut-off ≥5 for frequency of depression.
Cognitive functioning was measured with the cognitive functioning subscale of the EORTC QLQ-C30, range 0 – 100, lower scores indicate worse functioning,
cut-off <67 for frequency of cognitive impairment. Fatigue was measured with a Visual Analogue Scale, range 0 – 10, higher scores indicate more fatigue,
cut-off ≥4 for frequency of fatigue
aDifferences between older cancer patients and younger cancer patients
bDifferences between older cancer patients and older persons without cancer
(See figure on previous page.)
Fig. 2 Frequency and severity of psychosocial problems at baseline and one-year follow-up. Note: Depression was measured with the 15-item Geriatric
Depression Scale, range 0 – 15, higher scores indicate more depression, cut-off ≥5 for frequency of depression. Cognitive functioning was measured with
the cognitive functioning subscale of the EORTC QLQ-C30, range 0 – 100, lower scores indicate worse functioning, cut-off <67 for frequency of cognitive
impairment. Fatigue was measured with a Visual Analogue Scale, range 0 – 10, higher scores indicate more fatigue, cut-off ≥4 for frequency of fatigue
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(OR: 1.16; 95 % CI: 1.06 - 1.27). In line with the previous
analyses, also presence of fatigue at T0 significantly pre-
dicted fatigue at T1 (OR: 3.53; 95 % CI: 2.20 - 5.64). Other
factors that were associated with increased risk of fatigue
were being female (OR: 2.08; 95 % CI: 1.16 - 3.73) and
leaving school at age 15 – 18 years compared to leaving
school at age <15 years (OR: 1.95; 95 % CI: 1.06 - 3.61).
Sensitivity analyses
Imputing missing values as either best- or worst-case
scenario did not change the conclusion of our results.
For some variables such as the number of drugs taken as
chronic medication and the association with cancer ther-
apy, the worst- and best-case scenarios tipped the bal-
ance to significance. However, the lower level of the
95 % confidence interval was in this case never higher
than 1.01 (see Additional file 2: Table S2).
When the evolution of severity and frequency of de-
pression was stratified according to sex, OCP, especially
women experienced a significant increase in depression
from 7 % at T0 to 19 % at T1 (p < 0.001) (see Additional
file 3: Table S3). For male OCP were not able to show a
Table 3 Factors associated with psychosocial problems at one-year follow-up
Depression at T1 Cognitive functioning at T1 Fatigue at T1
N = 421 N = 429 N = 413
OR (95 % CI) OR (95 % CI) OR (95 % CI)
Baseline value of the problem 10.39 (4.65 - 23.22) 4.21 (2.56 - 6.93) 3.53 (2.20 - 5.64)
Ageing-related variables
Age: mean 0.97 (0.93 - 1.01) 1.00 (0.97 - 1.04) 1.00 (0.97 - 1.03)
Number of drugs: mean 1.08 (0.97 - 1.20) 1.03 (0.94 - 1.12) 1.16 (1.06 - 1.27)
Comorbidity: mean CCI score 1.10 (0.80 - 1.50) 0.96 (0.77 - 1.20) 1.18 (0.92 - 1.51)
Change in functional status
Not impaired 1 Reference 1 Reference 1 Reference
Was impaired 2.56 (0.69 - 9.54) 1.42 (0.62 - 3.25) 1.41 (0.67 - 2.94)
Became impaired 3.99 (1.14 - 13.90) 1.91 (0.86 - 4.24) 2.14 (1.04 - 4.43)
Persistently impaired 7.78 (2.60 - 23.29) 2.34 (1.21 - 4.54) 1.17 (0.65 - 2.11)
Socio-demographic variables
Gender (women) 0.56 (0.26 - 1.24) 0.91 (0.49 - 1.66) 2.08 (1.16 - 3.73)
Living conditions
With partner 1 Reference 1 Reference 1 Reference
With friends/family 2.54 (0.63 - 10.26) 1.08 (0.34 - 3.45) 0.87 (0.28 - 2.66)
Institutionalised 2.02 (0.30 - 13.69) 0.28 (0.03 - 2.86) 0.63 (0.09 - 4.20)
Alone 2.70 (1.31 - 5.56) 1.10 (0.61 - 1.97) 0.97 (0.55 - 1.71)
Age at leaving school
<15 years 1 Reference 1 Reference 1 Reference
15 – 18 years 0.91 (0.41 - 2.02) 1.18 (0.62 - 2.26) 1.95 (1.06 - 3.61)
>18 years 0.80 (0.32 - 2.02) 1.18 (0.58 - 2.40) 1.44 (0.74 - 2.80)
Cancer-related variables
Cancer treatment
No cancer 1 Reference 1 Reference 1 Reference
Surgery only 1.35 (0.31 - 5.76) 0.87 (0.29 - 2.61) 0.44 (0.17 - 1.15)
Surgery and RT/HT therapy or both 2.48 (0.97 - 6.36) 1.59 (0.76 - 3.32) 0.77 (0.39 - 1.53)
Surgery and CT with or without any combination RT, HT, TT 3.26 (1.20 - 8.87) 2.17 (0.99 - 4.78) 1.73 (0.80 - 3.72)
Othera / 1.28 (0.21 - 7.74) 0.82 (0.15 - 4.36)
Percentage correctly classified 86 % 76 % 71 %
Goodness-of-fit test 0.90 0.18 0.30
OR, Odds Ratio; 95 % CI, 95 % Confidence Interval; CCI, Charlson Comorbidity Index; RT, radiotherapy; HT, hormonal therapy; CT, chemotherapy; TT, targeted therapy
aOther cancer treatments consisted of people who received no surgery but instead any of the following combinations: chemotherapy only (N = 2), chemo- and
radiotherapy (N = 6), chemo- and targeted therapy (N = 1), hormonal therapy only (N = 2)
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difference, however numbers were small (N = 18). Also for
YCP both men and women experienced an increase in de-
pression. The results for men need to be interpreted with
caution as the number of men was small (N = 26) and at
baseline only one person reported depression. For ONC,
depression did not change neither in men nor women. For
cognitive functioning and fatigue results remained similar
when stratified according to sex. Cognitive impairment in-
creased slightly in the two cancer groups, which was only
significant in female OCP (p < 0.001). Again, the group of
male cancer patients was too small to formulate reliable
conclusions.
The evolution of depression, cognitive impairment,
and fatigue followed the same trend in breast and colo-
rectal cancer patients and the frequency and severity
was similar between breast and colorectal cancer pa-
tients at all time points (see Additional file 4: Table S4).
Discussion
In this paper, the occurrence of psychosocial problems
in OCP at time of cancer diagnosis and one year later
was studied. The frequency of depression increased and
cognitive functioning slightly worsened in the group of
OCP as well as YCP. However, OCP were not at higher
nor lower risk of depression, impaired cognitive func-
tioning, and fatigue compared to YCP. Compared to
ONC, the difference in cognitive functioning and fatigue
was small, and after one year of follow-up, only depres-
sion was more frequent in OCP compared to ONC. In
multivariate analyses, the main risk factors for psycho-
social problems were changes in functional status and
presence of baseline depression, fatigue or cognitive
impairment.
An important timeframe
The occurrence of psychosocial problems was studied at
time of cancer diagnosis and one year after a diagnosis
of cancer. This is a timeframe that often corresponds
with the transition from secondary to primary care, i.e.
the time when general practitioners (GPs) become the
first contact person again, especially for psychosocial is-
sues. Previous studies emphasised that the transition
from secondary to primary care is associated with in-
creased psychological distress [22, 23]. Our study also
showed more depression and some worsening of cogni-
tive functioning one year after cancer diagnosis. While
psychosocial care might be well organized around cancer
diagnosis and treatment within the hospital setting, there
is no consensus yet on the organization of cancer after-
care [24]. Whether or not GPs will claim a formal role
in cancer aftercare, their role will become more promin-
ent due to the increasing numbers of OCP and the shift
from inpatient to ambulatory care [25]. Hence, GPs but
also other primary and secondary health care providers
should be aware of the psychosocial problems cancer pa-
tients may encounter, also when primary cancer treatment
has ended. Furthermore, presence of the problem at base-
line was the main risk factor for psychosocial problems
one year after cancer diagnosis. This highlights the im-
portance of regular screening for psychosocial problems
and exchange of information on psychosocial functioning
between secondary and primary care professionals.
The impact of ageing: older cancer patients versus
younger cancer patients
Increasing age is associated with the accumulation of
personal and health-related losses and diminishing fi-
nancial and social resources, which may contribute to
increased vulnerability [26]. Therefore, it is not unlikely
that OCP may face more psychosocial problems com-
pared to YCP, e.g. more depression and more cognitive
problems.
Two cross-sectional studies showed that within the
group of OCP, increasing age was positively associated
with depression [26, 27]. Although there was no associ-
ation with chronological age in this study, multivariate
analyses showed that several ageing-related problems
were associated with psychosocial problems. For ex-
ample, becoming impaired or being persistently impaired
on functional status predicted all three selected psycho-
social problems, including depression. Also the mean
number of drugs taken as chronic medication predicted
the occurrence of fatigue and people who were living
alone were at increased risk for depression. As such,
adequate (social) support seems an essential element in
safeguarding psychosocial wellbeing of older people.
Adequate support may countervail the negative effects
of functional impairment, comorbidity, and living alone.
When comparing OCP and YCP, this study showed
that the occurrence of psychosocial problems was simi-
lar in both groups at time of cancer diagnosis and one
year later. These findings are consistent with those from
a recent cross-sectional study among older (≥60 years)
and younger (<60 years) patients undergoing cancer treat-
ment [10]. Another study showed that the level of depres-
sion was comparable in older (≥65 years) and younger
(45 – 65 years) cancer patients 3 months, 15 months,
and 8 years after cancer diagnosis [28].
However, in contrast to our findings, several other
studies reported better psychosocial functioning in OCP
compared to YCP (see for example [9, 10, 29]). The
definition of ’older’ and ‘younger’ patients might explain
these inconsistent results as this varies widely across dif-
ferent studies [26]. Cohen et al. emphasize that studies
showing a better functioning in OCP often used a cut-
off for old age at relatively young age; 50 or 60 years
[26]. Until now, there is no clear consensus on the defin-
ition of an OCP. However, the International Society of
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Geriatric Oncology uses 70 years and above as age cut-
off for an OCP [14].
The impact of cancer: older cancer patients versus older
persons without cancer
OCP often fare worse, physically as well as mentally,
compared to people of the same age without cancer
[7, 8]. In this study, the prevalence of depression at
one-year follow-up in OCP was twice the percentage
of ONC, and also cancer patients who received
chemotherapy were at increased risk for depression
compared to people without cancer. However, for cogni-
tive functioning and fatigue, OCP and ONC were not dif-
ferent after one year of follow-up. In contrast with our
results, a recent study among long-term cancer survivors
(15 years since diagnosis) showed no difference between
OCP and healthy controls with respect to depression [6].
A possible explanation for these different findings is that
the first year after diagnosis is strongly affected by the
consequences of cancer and its treatment, while in the
long term psychological functioning of cancer survivors
may be more affected by ageing [28]. In contrast, we could
not show a significant association between cancer treat-
ment and fatigue or subjective cognitive functioning. Fa-
tigue may be secondary to the physical and psychological
stress associated with cancer and its treatment [30]. Fur-
thermore, comorbidity may play an important role in the
occurrence of fatigue; the drugs as well as the underlying
comorbidity may contribute to the occurrence of fatigue
[30, 31]. This may explain why the prevalence fatigue was
not higher in cancer patients compared to people without
cancer. In our study, comorbidity as measured by the CCI
was not significantly associated with fatigue, but the
number of drugs taken as chronic medication signifi-
cantly predicted the occurrence of fatigue. However, it
was beyond the scope of this study to investigate the
role of specific cancer treatment regimens on cognitive
functioning or fatigue.
Strengths and limitations
The key strengths of this study are its longitudinal de-
sign, the two control groups that allow us to disentangle
the effects of ageing and cancer, and the use of measure-
ment instruments that are appropriate in older persons.
Nevertheless, this study has some limitations. For ex-
ample, the GDS-15, a well-validated screening instru-
ment for depression in an older (cancer) population
[11], may not be as suitable for YCP. However, we do
not believe this biased our results. The GDS was de-
signed to reduce the focus on somatic symptoms of
depression [15]. This is an important feature for the
identification of depression in cancer patients. Identifica-
tion of depression in cancer patients in especially chal-
lenging because the symptoms of depression are often
similar to those of somatic diseases or their treatment
[32]. Furthermore, Cronbach’s alpha was also high for
YCP (0.77). In contrast we found relatively low Cron-
bach’s alpha for subjective cognitive functioning, in par-
ticular in older persons without cancer. Hence results
with respect to subjective cognitive functioning should
be interpreted with caution. Nonetheless, Cronbach’s
alpha was relatively low in the two groups of cancer pa-
tients as well and also previous studies in cancer patients
have reported a wide range of Cronbach’s alphas for this
subscale [33]. Another limitation is loss to follow-up and
incomplete data. Twenty-two percent of patients were
lost to follow-up. This is comparable with other large
health and ageing studies in Europe (e.g. 22 % loss to
follow-up in the English Longitudinal Study of Ageing)
[34]. Furthermore, patients lost to follow-up were com-
parable to those available for analyses and our results
were robust for imputing yes or no for missing values in
a sensitivity analysis. Loss to follow-up may jeopardise
the power of the study, for example the confidence in-
tervals for depression were wide. This lack of precision
should be taken into account when generalizing the
results. With respect to the influence of sex, the
generalizability of our results may be limited for men,
because the majority of cancer patients in this study
were women. It is known, for example, that women are
more likely to report feelings of depression compared to
men [35]. When stratified according to sex, the increase
in depression was indeed only apparent in female OCP.
However, we were not able to formulate any conclusions
on male patients as a separate group, as the number of
men was limited. Additionally, also the selection of breast
and colorectal cancer patients with a relatively good prog-
nosis needs to be considered when generalizing these
results.
Conclusion
This study showed that OCP as well as YCP face in-
creasing levels of depression and increasing difficulties
in cognitive functioning over the course of one year
after a diagnosis of cancer, a timeframe that corre-
sponds with the transition from secondary to primary
care. The main risk factor for psychosocial problems
was presence of the problem at baseline. Hence, health
care providers should be aware of the psychosocial
problems cancer patients may encounter, also when
primary cancer treatment has ended. Furthermore, this
highlights the importance of regular screening for psy-
chosocial problems and exchange of information on
psychosocial functioning between different health care
providers and settings during the treatment and follow-up
trajectory of cancer patients. More longitudinal studies
with similar control groups are needed in order to confirm
our results.
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